News

frenchweb-highlights-rebrains-e3-7-million-seed-funding-for-parkinsons-disease-innovation

20 March 2024

FrenchWeb Highlights RebrAIn’s €3.7 Million Seed Funding for Parkinson’s Disease Innovation

We are thrilled to share that FrenchWeb has featured RebrAIn for securing €3.7 million in seed funding to advance our AI-driven solutions for treating Parkinson’s Disease.

Led by Karista and supported by Nouvelle Aquitaine Co-Investissement, this funding will accelerate the international expansion of our innovative platform, OptimDBS, which aims to simplify and standardize Deep Brain Stimulation procedures. This significant investment underscores our commitment to enhancing patient outcomes and making neurosurgical treatments more accessible.

Read the full story here (in French).

An English translation by Google is available here.

back to the news page

More news

RebrAIn Co-Founders to Present Innovative VIM Targeting Techniques at WSSFN Biennial Meeting

Sep 3, 2024

RebrAIn is excited to announce that its co-founders, Prof. Emmanuel Cuny, MD, and Prof. Nejib Zemzemi, PhD, will be presenting groundbreaking research on VIM targeting techniques at the upcoming World Society for Stereotactic and Functional Neurosurgery (WSSFN)...

RebrAIn Achieves Second FDA 510(k) Clearance, Advancing AI-Powered Neurosurgical Targeting

Aug 13, 2024

RebrAIn is proud to announce its second FDA 510(k) clearance for the OptimMRI software, marking another significant milestone in our mission to revolutionize neurosurgical targeting through cutting-edge AI technology. This clearance expands our capabilities to assist...

MedTech Strategist Features RebrAIn’s Precision Targeting Solutions for Parkinson’s Disease

May 22, 2024

We are delighted to share that MedTech Strategist has featured RebrAIn in their latest issue.The article explores how our supervised AI-driven platform, OptimMRI, simplifies precision targeting for Deep Brain Stimulation (DBS) in Parkinson’s Disease. By enhancing...